- cafead Sep 21, 2020 at 10:52: AM
via Shares of the Chinese anti-cancer cell therapy specialist Legend Biotech (NASDAQ:LEGN) are poised for a rough session today. Ahead of the opening bell Monday morning, the biotech's stock fell by as much as 15.8% in response to the news that the Customs Anti-Smuggling Department of the People's Republic of China (PRC) inspected offices associated with both its parent majority shareholder, GenScript Biotech Corporation, and some of its own subsidiaries in the country.
article source
article source